ApoA-I is a major
protein component of
high-density lipoprotein (HDL) that is widely known for regulating
cholesterol trafficking and inflammatory and immune responses and for protecting against
atherosclerosis.
ApoA-I is generally considered to be synthesized in the liver (hepatocytes) and small intestine (enterocytes). However, computer analysis of
ApoA-I has shown that the
ApoA-I gene may be expressed in not only hepatocytes and enterocytes but also monocyte-macrophage cells, dendritic cells (DCs) and T cells.
ApoA-I expression has been detected in THP-1 monocytes and macrophages, peripheral blood mononuclear cells (PBMCs) from postmenopausal women, human PBMC-derived monocytes and macrophages, mouse peritoneal macrophages, etc. Endogenous
ApoA-I in macrophages has anti-inflammatory and
cholesterol efflux effects. However, our understanding of the detailed roles of macrophage-synthesized
ApoA-I is still at an early stage and very limited. More experiments are needed to elucidate the exact roles of endogenous
ApoA-I in macrophages. Several lines of evidence indicate that recombinant exogenous human
ApoA-I in mouse macrophages increases
cholesterol efflux and thus reduces
atherosclerosis development. Considering the antiatherogenic effect of exogenous
ApoA-I overexpression in mouse macrophages, better understanding the role and mechanisms underlying macrophage-synthesized
ApoA-I in
atherosclerosis will enable macrophage-synthesized
ApoA-I therapy to open new avenues for reducing the risk of
atherosclerosis.